Alcon noted additional operational updates alongside the announcement.
Martin Harp
Advertisement
Articles by Martin Harp
At 12 weeks posttreatment, all 4 of the patients showed improvement in the form of a lower logMAR.
The company is developing a one-time, non-AAV2 gene replacement therapy to restore, treat, and prevent blindness of patients with RPE65 mutation-associated retinopathies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
M. Peter Marinkovich, MD, on Integrating Gene Therapy into Clinical Practice for Dermatologists
2
Quarter Century Update: How can Partnerships Between Academia, Biotech, and Pharma be Better Structured?
3
Quarter Century Update: Platform Approaches and Industry Investment
4
